SCHEMBL25759801

SCHEMBL25759801

CC(C)c1cccc2c1O[C@](C)(C(C)C)O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRB2 P47870 2/20 0.38
FAAH O00519 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
GABRB1 P18505 1/20 0.38
PTGS1 P23219 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2C P28335 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
HTR2B P41595 1/20 0.38
GABRA2 P47869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25465411 1.00 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL7745010 0.83 ALDH1A1 (0.43) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL15887374 0.80 GABRA1 (0.36) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL10122079 0.78 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL9962275 0.78 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL23980767 0.76 GABRA1 (0.33) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL13821303 0.75 KDM4E (0.34) LMNATSHR
SCHEMBL29801762 0.71 GABRA1 (0.46) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL5503549 0.71 GABRA1 (0.46) GABRA1GABRG2GABRB3GABRB2FAAH
SCHEMBL24390046 0.70 GABRA1 (0.44) GABRA1GABRG2GABRB3GABRB2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322758-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR GABRA1 884/4885GABRG2 1059/4885GABRB3 1252/4885
US-20230322758-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR GABRA1 318/4885GABRG2 343/4885GABRB3 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.